Stay updated with breaking news from Craig Eagle. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
COSMOS study shows Guardant Reveal™ blood test highly predictive for disease recurrence in patients with early-stage colon cancer without need for tissue specimen ...
Spotlight sessions highlight role of Guardant blood tests in tissue-free detection of minimal residual disease and predictive impact of ctDNA genomic profiling MRD study found ctDNA detection...
Guardant Health, Inc. , a leading precision oncology company, will present data showing the utility of liquid biopsy tests in the management of breast cancer patients at the San Antonio Breast Cancer Symposium, December 5-9 in San Antonio, Texas....
PALO ALTO, Calif., October 23, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that initial results from the PEGASUS trial suggest liquid biopsy may be used in post-surgical clinical management to reduce unnecessary toxicity from chemotherapy and improve the response to standard chemotherapy regimens in patients with stage III or high-risk stage II colon cancer. Results from the trial, which is an ISS study sponsored by IFOM ETS – the AIRC Institut
01.09.2023 - Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today issued the following statement about the closure of COBRA, a minimum residual disease (MRD) study. The COBRA study was designed to evaluate the effectiveness of using ...